Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent

Krystal Biotech (NASDAQ:KRYS) announced Thursday a revamped product pipeline after a decision to prioritize studies for an inhaled version of its antitumor candidate KB707 targeted at non-small cell lung cancer.

The decision followed an End of Phase 2 meeting granted by the FDA to discuss the registrational path for inhaled KB707 based on the immunotherapy's early efficacy results, Krystal Biotech (NASDAQ:KRYS) said.

As a result, the Pittsburgh, Pennsylvania-headquartered biotech will pause enrollment in its OPAL-1 Phase 1/2 open-label trial designed to evaluate intratumoral KB707 in patients with solid tumors.

However, enrollment in its KYANITE-1 Phase 1/2 trial, which evaluates inhaled KB707 in solid tumors of the lung, will continue.

The company added that it will further revise R&D plans for intratumoral KB707 based on safety and efficacy data from OPAL-1, as patients in that study will continue to be monitored.